Iantrek Launches AlloFlo Uveo in the U.S., Introducing First Surgical Treatment for Uveoscleral Pathway in Glaucoma

Iantrek has officially announced the U.S. commercial launch of AlloFlo Uveo, the first surgical treatment specifically developed to target the uveoscleral pathway in glaucoma management.

Backed by Strong Financial Support and Strategic Expansion

The launch follows Iantrek’s successful $42 million Series C financing round, which the company reports will fund its commercial expansion, surgeon education initiatives, and continued clinical innovation. With this backing, Iantrek aims to rapidly scale access to AlloFlo Uveo across the U.S. glaucoma community.

A New Surgical Approach Targeting the Uveoscleral Pathway in Glaucoma

AlloFlo Uveo represents a bio-interventional approach to enhancing aqueous humor outflow through the uveoscleral pathway, an often-underutilized drainage route in glaucoma treatment. Unlike traditional MIGS devices, AlloFlo Uveo is engineered to maintain the patency of a surgically created cleft, supporting long-term outflow and providing a durable alternative for patients at risk of irreversible vision loss.

“Approximately 2.5 million eyes in the U.S. have undergone previous MIGS procedures, but many are now experiencing waning efficacy,” said Adam Szaronos, CEO of Iantrek. “Our early-release program has surpassed all expectations, validating the large unmet need for uveoscleral enhancement as well as strong surgeon adoption of our AlloFlo Uveo technology. Our sights are now set on scaling a world-class commercial organization to support this growing demand with glaucoma surgeons.”

Clinical Validation and Surgeon Adoption

To date, over 100 surgeons globally have partnered with Iantrek, performing thousands of AlloFlo procedures. The treatment’s clinical utility and long-term potential have been supported by seven peer-reviewed publications, highlighting both safety and efficacy.

Glaucoma surgeon and Iantrek Medical Monitor, Dr. Arsham Sheybani, emphasized the significance of the technology:

“As a practicing glaucoma surgeon, I’ve seen firsthand the limitations of existing surgical options. AlloFlo Uveo is unique because it provides a minimally invasive, reproducible method for tapping into an underutilized outflow pathway. This is a valuable addition to our surgical armamentarium.”